IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients

(2011) Mrinal M. Patnaik et al.   AMERICAN JOURNAL OF HEMATOLOGY

Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation

(2011) Tatsuhiro Shibata et al.   AMERICAN JOURNAL OF PATHOLOGY

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

(2011) C. L. Green et al.   BLOOD

Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

(2011) O Abdel-Wahab et al.   LEUKEMIA

p53 Lesions in Leukemic Transformation

(2011) Ashot Harutyunyan et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

(2010) S. Schnittger et al.   BLOOD

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

(2010) S. Abbas et al.   BLOOD

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

(2010) C. L. Green et al.   BLOOD

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

(2010) F. Thol et al.   BLOOD

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

(2010) F. Thol et al.   HAEMATOLOGICA

Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group

(2010) Nicolas Boissel et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor

(2010) Katharina Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)

(2010) A Pardanani et al.   LEUKEMIA

IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis

(2010) S Soverini et al.   LEUKEMIA

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

(2010) A Tefferi et al.   LEUKEMIA

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

(2010) D Caramazza et al.   LEUKEMIA

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms

(2010) A Pardanani et al.   LEUKEMIA

LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

(2010) A Pardanani et al.   LEUKEMIA

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

(2010) W-C Chou et al.   LEUKEMIA

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms

(2010) R Jäger et al.   LEUKEMIA

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

(2010) O Kosmider et al.   LEUKEMIA

IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia

(2010) D Caramazza et al.   LEUKEMIA

Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms

(2010) Anthony Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

(2009) A Tefferi et al.   LEUKEMIA

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

(2009) A Tefferi et al.   LEUKEMIA

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Risk factors for leukemic transformation in patients with primary myelofibrosis

(2008) Jocelin Huang et al.   CANCER

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

(2008) A M Vannucchi et al.   LEUKEMIA

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE